Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas
NCT02523014Phase 2Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2015
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib, GSK2256098, capivasertib, abemaciclib in meningioma, sponsored by Cancer and Leukemia Group B. Started Sep 2015; status: recruiting.
02
Drugs
vismodegibGSK2256098capivasertibabemaciclib
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT02523014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523014.